Developing and Testing of an Original Molecular Panel for Evaluating the Efficacy of Acute Myeloid Leukemia Treatment and Early Diagnosis of Relapses by Quantitative Real-Time PCR

Nikolai Nikolaevich Mamaev, Ya.V. Krylova, M.M. Kanunnikov, A.I. Shakirova, A.M. Sadykov, I.M. Barkhatov, B.I. Ayubova, T.L. Gindina, L.S. Zubarovskaya,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-3-275-291

Fundamental studies of hematopoiesis have confirmed the existence of WT1-expressing lineage-differentiated hematopoietic precursor cells, which are functionally related with BAALC-expressing hematopoietic stem cells (HSCs), on the one hand, and with WT1-expressing blast elements, on the other. The data obtained provided the basis for analyzing the mixed cohort of patients with CBF-positive and FLT3-mutated variants of acute myeloid leukemia (AML) for developing a panel of molecular markers. The purposes of this panel are therapy efficacy assessment and early diagnosis of relapses alternative to the initial BAALC-expressing HSC clones. The developed combined approach was tested on a big clinical case series including the data from 114 patients with CBF+ (n = 63) and FLT3+ (n = 51) AML variants. The suggested original molecular diagnostic panel based on the serial measurements of BAALC and WT1 expression levels combined with simultaneous determination of the blast content in bone marrow aspirates seems to be a promising and useful tool for both research and clinical practice.

  1. Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA. 2001;98(24):3901–6. doi: 10/1073/pnas.241525498. DOI: https://doi.org/10.1073/pnas.241525498
  2. Baldus CD, Tanner SM, Kusewitt DF, et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol. 2003;31(11):1051–6. DOI: https://doi.org/10.1016/j.exphem.2003.08.004
  3. Baldus C, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood. 2003;102(5):1613–8. doi: 10.1182/blood-2003-02-0359. DOI: https://doi.org/10.1182/blood-2003-02-0359
  4. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10(3):201–9. doi: 10.1038/nri2726. DOI: https://doi.org/10.1038/nri2726
  5. Morita R, Masamotyo Y, Kataoka K, et al. BAALC potentiates oncogenic ERK pathway through interactions with MEKK and KLF4. Leukemia. 2015;29(11):2248–56. doi: 10.1038/leu.2015.137. DOI: https://doi.org/10.1038/leu.2015.137
  6. Wilson NK, Kent DG, Buettner F, et al. Combined Single-Cell Functional and Gene Expression Analysis Resolves Heterogeneity within Stem Cell Populations. Cell Stem Cell. 2015;16(6):712–24. doi: 10.1016/j.stem.2015.04.004. DOI: https://doi.org/10.1016/j.stem.2015.04.004
  7. Won EJ, Kim H-R, Park R-Y, et al. Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications. BMC Cancer. 2015;15:217. doi: 10.1186/s12885-015-1233-x. DOI: https://doi.org/10.1186/s12885-015-1233-x
  8. Канунников М.М., Мамаев Н.Н., Гиндина Т.Л. и др. BAALC-экспрессирующие лейкозные гемопоэтические стволовые клетки и их место в изучении CBF-позитивных острых миелоидных лейкозов у взрослых и детей. Клиническая онкогематология. 2023;16(4):387–98. doi: 10.21320/2500-2139-2023-16-4-387-398. [Kanunnikov M.M., Mamaev N.N., Gindina T.L., et al. BAALC-Expressing Leukemia Hematopoietic Stem Cells and Their Place in the Study of CBF-Positive Acute Myeloid Leukemias in Children and Adults. Clinical oncohematology. 2023;16(4):387–98. doi: 10.21320/2500-2139-2023-16-4-387-398. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2023-16-4-387-398
  9. Yoon J-H, Kim H-J, Shin S-H, et al. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Eur J Haematol. 2013;91(2):112–21. doi: 10.1111/ejh.12142. DOI: https://doi.org/10.1111/ejh.12142
  10. Мамаев Н.Н., Канунников М.М., Шакирова А.И. и др. Теоретические и практические аспекты изучения фракций BAALC-экспрессирующих гемопоэтических стволовых клеток у больных острыми миелоидными лейкозами с мутациями в гене FLT3. Клиническая онкогематология. 2025;18(1):73–85. doi: 10.21320/2500-2139-2025-18-1-73-85. [Mamaev N.N., Kanunnikov M.M., Shakirova A.I., et al. Theoretical and Practical Aspects of Studying the Fractions of BAALC-Expressing Hematopoietic Stem Cells in Acute Myeloid Leukemia Patients with FLT3 Mutations. Clinical oncohematology. 2025;18(1):73–85. doi: 10.21320/2500-2139-2025-18-1-73-85. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2025-18-1-73-85
  11. Shakirova AI, Barkhatov IM, Churkina AI, et al. Prognostic significance of BAALC overexpression in patients with AML during the posttransplant period. Cell Ther Transplant. 2018;7(2):54–63. doi: 10.18620/ctt-1866-8836-2018-7-2-54-63. DOI: https://doi.org/10.18620/ctt-1866-8836-2018-7-2-54-63
  12. Shakirova AI, Mamaev NN, Barkhatov IM, et al. Clinical significance of BAALC overexpression for predicting post-transplant relapses in acute myeloid leukemia. Cell Ther Transplant. 2019;8(2):45–57. doi: 10.18620/ctt-1866-8836-2019-8-2-45-57. DOI: https://doi.org/10.18620/ctt-1866-8836-2019-8-2-45-57
  13. Мамаев Н.Н., Шакирова А.И., Бархатов И.М. и др. Ведущая роль BAALC-экспрессирующих клеток-предшественниц в возникновении и развитии посттрансплантационных рецидивов у больных острыми миелоидными лейкозами. Клиническая онкогематология. 2020;13(1):75–88. doi: 10.21320/2500-2139-2020-13-1-75-88. [Mamaev N.N., Shakirova A.I., Barkhatov I.M., et al. Crucial Role of BAALC-Expressing Progenitor Cells in Emergence and Development of Post-Transplantation Relapses in Patients with Acute Myeloid Leukemia. Clinical oncohematology. 2020;13(1):75–88. doi: 10.21320/2500-2139-2020-13-1-75-88. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2020-13-1-75-88
  14. Mamaev NN, Shakirova AI, Gindina TL, et al. Quantitative study of BAALC- and WT1-expressing cell precursors in the patients with different cytogenetic and molecular AML variants treated with Gemtuzumab ozogamicin and hematopoietic stem cell transplantation. Cell Ther Transplant. 2021;10(1):55–62. doi: 10.18620/ctt-1866-8836-2021-10-1-55-62. DOI: https://doi.org/10.18620/ctt-1866-8836-2021-10-1-55-62
  15. Mamaev NN, Shakirova AI, Barkhatov IM, et al. Evaluation of BAALC- and WT1-expressing leukemic cell precursors in pediatric and adult patients with EVI1-positive AML by means of quantitative real-time polymerase chain reaction (RT-qPCR). Cell Ther Transplant. 2021;10(2):54–9. doi: 10.18620/ctt-1866-8836-2021-10-2-54-59. DOI: https://doi.org/10.18620/ctt-1866-8836-2021-10-2-54-59
  16. Mamaev NN, Shakirova AI, Kanunnikov MM. BAALC-expressing Cells in Acute Leukemias and Myelodysplastic Syndromes: Present and Future. Generis; 2022. 91 p.
  17. Mamaev NN, Baykov VV, Shakirova AI, et al. Near Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with impressive Response to Venetoclax. Insights Blood Disord. 2022;1(1):1–5. DOI: https://doi.org/10.33425/2771-9073.1007
  18. Мамаев Н.Н., Латыпова М.В., Шакирова А.И. и др. Роль BAALC-экспрессирующих лейкозных клеток-предшественниц в патогенезе миелодиспластических синдромов. Клиническая онкогематология. 2022;15(1):62–8. doi: 10.21320/2500-2139-2022-15-1-62-68. [Mamaev N.N., Latypova M.V., Shakirova A.I., et al. The Role of BAALC-Expressing Leukemia Precursor Cells in the Pathogenesis of Myelodysplastic Syndromes. Clinical oncohematology. 2022;15(1):62–8. doi: 10.21320/2500-2139-2022-15-1-62-68. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2022-15-1-62-68
  19. Ольховский И.А., Горбенко А.С., Столяр М.А. и др. Исследование мРНК генов WT1, BAALC, EVI1, PRAME И HMGA2 в образцах венозной крови при острых лейкозах. Клиническая лабораторная диагностика. 2022;67(10):613–20. doi: 10.51620/0869-2084-2022-67-10-613-620. [Olkhovskiy I.A., Gorbenko A.S., Stolyar M.A., et al. Study of mRNA of WT1, BAALC, EVI1, PRAME and HMGA2 genes in whole blood samples. Klinicheskaya Laboratornaya Diagnostika. 2022;67(10):613–20. doi: 10.51620/0869-2084-2022-67-10-613-620. (In Russ)] DOI: https://doi.org/10.51620/0869-2084-2022-67-10-613-620
  20. Mamaev NN, Shakirova AI, Barkhatov IM, et al. Crucial role of BAALC-expressing leukemic precursors in patients with acute myeloid leukemia. Hematol Transfus Int J. 2020;8(6):1227–31. doi: 10.15406/htij.2020.08.00240. DOI: https://doi.org/10.15406/htij.2020.08.00240
  21. Mamaev NN, Shakirova AI, Barkhatov IM, et al. New opportunities for assay of leukemia initiating cells (LICs) participating in post-transplant relapse development in the patients with acute myeloid leukemia. 3rd Annual IACH Meeting, 1–3 October, 2020, Paris. Report #12.
  22. Mamaev NN, Shakirova AI, Gindina TL, et al. New insights into the nature of the 5q- deletion syndrome based on quantitative measurement of BAALC-expressing stem cell burdens. J Hematol Res. 2023;10(1):6–10. doi: 10.12974/2312-5411.2023.10.02. DOI: https://doi.org/10.12974/2312-5411.2023.10.02
  23. Mamaev NN, Osipova AA, Karpunina UD, et al. First experience with BAALC-expressing leukemia stem cell fraction in juvenile myelomonocytic leukemia patients treated by hematopoietic stem cell transplantation. Cell Ther Transplant. 2024;13(2):32–40. doi: 10.18620/ctt-1866-8836-2024-13-2-32-40. DOI: https://doi.org/10.18620/ctt-1866-8836-2024-13-2-32-40
  24. Mamaev NN, Shakirova AI, Kanunnikov MM, et al. BAALC-expressing stem cell fractions: studies in patients with FLT3-mutated and juvenile myelomonocytic leukemias. Hematol Transfus Int J. 2025;13(1):5‒14. doi: 10.15406/htij.2025.13.00344. DOI: https://doi.org/10.15406/htij.2025.13.00344
  25. Mamaev NN, Shakirova AI, Gindina TL. BAALC-Expressing Stem Cells in Acute Leukemia and Myelodysplastic Syndromes. In: N Rezaei (ed). Comprehensive Hematology and Stem Cell Research. Elsevier; 2025. pp. 335–43. DOI: https://doi.org/10.1016/B978-0-443-15717-2.00078-0
  26. Call KM, Gieser T, Ito Cl, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor gene locus. Cell. 1990;60(3):509–20. doi: 10.1016/0092-8674(90)90601-a. DOI: https://doi.org/10.1016/0092-8674(90)90601-A
  27. Rose EA, Gieser T, Jones C, et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms’ tumor gene. Cell. 1990;60(3):495–508. doi: 10:1016/0092-8674(90)90600-j. DOI: https://doi.org/10.1016/0092-8674(90)90600-J
  28. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115–21. doi: 10.1038/sj.leu.2402675. DOI: https://doi.org/10.1038/sj.leu.2402675
  29. Cilloni D, Gottardi E, Fava M, et al. Usefulness of quantitative assessment of the WT1 gene transcript as a marker of minimal residual disease detection. Blood. 2003;102(2):773–4. doi: 10.1182/blood-2003-03-0980. DOI: https://doi.org/10.1182/blood-2003-03-0980
  30. Cilloni D, Saglio G. WT1 as universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol. 2004;112(1–2):79–84. doi: 10.1159/000077562. DOI: https://doi.org/10.1159/000077562
  31. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–201. doi: 10.1200/JCO.2009.22.4865. DOI: https://doi.org/10.1200/JCO.2009.22.4865
  32. Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93(6):921–4. doi: 10.3324/haematol.12165. DOI: https://doi.org/10.3324/haematol.12165
  33. Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2009;82(1):61–8. doi: 10.1111/j.1600-0609.2008.01158.x DOI: https://doi.org/10.1111/j.1600-0609.2008.01158.x
  34. Candoni A, Toffoletti E, Gallina R, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant. 2011;25(2):308–16. doi: 10.1111/j.1399-0012.2010.01251.x. DOI: https://doi.org/10.1111/j.1399-0012.2010.01251.x
  35. Messina C, Candoni A, Carraba M, et al. Wilms tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic stem cells predict relapse risk in patients autographted for acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(10):1586–91. doi: 10.1016/j.bbmt.2014.06.017. DOI: https://doi.org/10.1016/j.bbmt.2014.06.017
  36. Messina C, Sala E, Carraba M, et al. Early post-allogeneic transplantation WT1 transcript positivity predicts AML relapse. 40th EBMT Meeting, Italy, 2014. Abstract P239.
  37. Candoni A, De Marchi F, Zanini F, et al. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Exp Hematol. 2017;49:25–33. doi: 10.1016/j.exphem.2017.01.005. DOI: https://doi.org/10.1016/j.exphem.2017.01.005
  38. Candoni A, De Marchi F, Zannini F, et al. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Leuk Res. 2017;63:22–7. doi: 10.1016/j.leukres.2017.10.010. DOI: https://doi.org/10.1016/j.leukres.2017.10.010
  39. Lazzarotto D, Candoni A. The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia. J Clin Med. 2022;11(12):3306. doi: 10.3390/jcm11123306. DOI: https://doi.org/10.3390/jcm11123306
  40. Kwon M, Martinez-Laperche C, Infante M, et al. Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms’ Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism. Biol Blood Marrow Transplant. 2012;18(8):1235–42. doi: 10.1016/j.bbmt.2012.01.012. DOI: https://doi.org/10.1016/j.bbmt.2012.01.012
  41. Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. Cancer Med. 2016;5(2):265–74. doi: 10.1002/cam4.593. DOI: https://doi.org/10.1002/cam4.593
  42. Israyelyan A, Goldstein L, Tsai W, et al. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(1):26–33. doi: 10.1038/bmt.2014.209. DOI: https://doi.org/10.1038/bmt.2014.209
  43. Frairia C, Aydin S, Audisio E, et al. Post-remission and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. Leuk Res. 2017;61:10–7. doi: 10.1016/j.leukres.2017.08.008. DOI: https://doi.org/10.1016/j.leukres.2017.08.008
  44. Hao Y, Cheng Y, Wu Q, et al. Combined usage of Wilms’ tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Exper Ther Med. 2018;15(2):1403–9. doi: 10.3892/etm.2017.5547. DOI: https://doi.org/10.3892/etm.2017.5547
  45. Namdaroĝlu S, Başci S, Candir BA, et al. Role of WT1 in Measurable Residual Disease Follow-Up in the Allogeneic Stem Cell Transplant Setting. J Clin Med. 2024;13(17):5145. doi: 10.3390/jcm13175145. DOI: https://doi.org/10.3390/jcm13175145
  46. Shimada A, Taki T, Koga D, et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD has prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;96(4):469–76. doi: 10.1007/s12185-012-1163-1. DOI: https://doi.org/10.1007/s12185-012-1163-1
  47. Valkova V, Polak J, Markova M, et al. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. Clin Transplant. 2013;27(1):E21–E29. doi: 10.1111/ctr.12046. DOI: https://doi.org/10.1111/ctr.12046
  48. Chea M, Rigolot L, Canali A, et al. Minimal Residual Disease in Acute Myeloid Leukemias: Old and New Concepts. Int J Mol Sci. 2024;25(4):2150. doi: 10.3390/ijms25042150. DOI: https://doi.org/10.3390/ijms25042150
  49. Goel H, Panday AK, Kumar R. RNA Sequencing Identifies WT1 Overexpression as a Predictor of Poor Outcomes in Acute Myeloid Leukemia. Cancers. 2025;17(11):1818. doi: 10.3390/cancers17111818. DOI: https://doi.org/10.3390/cancers17111818
  50. Pozzi S, Geroldi S, Tedone E, et al. Leukemia relapse after allogeneic transplants for acute myeloid leukemia: predictive role of WT1 expression. Br J Haematol. 2013;160(4):593–9. doi: 10.1111/bjh.12181. DOI: https://doi.org/10.1111/bjh.12181
  51. Ujj Z, Buglyo G, Udvardy M, et al. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes. Pathol Oncol Res. 2016;22(1):2017–21. doi: 10.1007/s12253-015-0002-0. DOI: https://doi.org/10.1007/s12253-015-0002-0
  52. Di Grazia C, Pozzi S, Geroldi S, et al. WT-1 Expression and pre-Emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hematopoietic Stem Cell Transplant. Biol Bone Marrow Transplant. 2016;22(7):1242–6. doi: 10.1016/j.bbmt.2016.03.005. DOI: https://doi.org/10.1016/j.bbmt.2016.03.005
  53. Madaci L, Farnault L, Abbou N, et al. Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia/Myelodysplastic Neoplasms. Cancers (Basel). 2023;15(13):3280. doi: 10.3390/cancers15133280. DOI: https://doi.org/10.3390/cancers15133280
  54. Мамаев Н.Н., Горбунова А.В., Бархатов И.М. и др. Молекулярный мониторинг течения острых миелоидных лейкозов по уровню экспрессии гена WT1 после аллогенной трансплантации гемопоэтических стволовых клеток. Клиническая онкогематология. 2015;8(3):309–20. doi: 10.21320/2500-2139-2015-8-3-309-320. [Mamaev NN., Gorbunova AV., Barkhatov I.M., et al. Molecular Monitoring of WT1 Gene Expression Level in Acute Myeloid Leukemias after Allogeneic Hematopoietic Stem Cell Transplantation. Clinical oncohematology. 2015;8(3):309–20. doi: 10.21320/2500-2139-2015-8-3-309-320. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2015-8-3-309-320
  55. Мамаев Н.Н., Гудожникова Я.В., Горбунова А.В. Гиперэкспрессия гена WT1 при злокачественных опухолях системы крови: теоретические и клинические аспекты (обзор литературы). Клиническая онкогематология. 2016;9(3):257–64. doi: 10.21320/2500-2139-2016-9-3-257-264. [Mamaev N.N., Gudozhnikova Ya.V., Gorbunova A.V., et al. WT1 Gene Overexpression in Oncohematological Disorders: Theoretical and Clinical Aspects (Literature Review). Clinical oncohematology. 2016;9(3):257–64. doi: 10.21320/2500-2139-2016-9-3-257-264. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2016-9-3-257-264
  56. Гиндина Т.Л., Мамаев Н.Н., Бондаренко С.Н. и др. Результаты аллогенной трансплантации гемопоэтических стволовых клеток у больных острым миелоидным лейкозом c t(8;21)(q22;q22)/RUNX1-RUNX1T1 и дополнительными цитогенетическими аномалиями. Клиническая онкогематология. 2016;9(2):148–54. doi: 10.21320/2500-2139-2016-9-2-148-154. [Gindina T.L., Mamaev N.N., Bondarenko S.N., et al. Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia with t(8;21)(q22;q22)/RUNX1-RUNX1T1 and Additional Cytogenetic Abnormalities. Clinical oncohematology. 2016;9(2):148–54. doi: 10.21320/2500-2139-2016-9-2-148-154. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2016-9-2-148-154
  57. Мамаев Н.Н., Гудожникова Я.В., Гиндина Т.Л. и др. Эффективность химиотерапии у больных острыми лейкозами с резистентностью к предшествующему стандартному лечению по данным серийного измерения уровня экспрессии гена WT1. Клиническая онкогематология. 2018;11(1):78–88. doi: 10.21320/2500-2139-2018-11-1-78-88. [Mamaev N.N., Gudozhnikova Ya.V., Gindina T.L., et al. Efficacy of Chemotherapy in Acute Leukemia Patients Resistant to Previous Standard Treatment According to the Series Measurement of WT1 Gene Expression. Clinical oncohematology. 2018;11(1):78–88. doi: 10.21320/2500-2139-2018-11-1-78-88. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2018-11-1-78-88
  58. Гудожникова Я.В., Мамаев Н.Н., Бархатов И.М. и др. Результаты молекулярного мониторинга в посттрансплантационный период с помощью серийного исследования уровня экспрессии гена WT1 у больных острыми миелоидными лейкозами. Клиническая онкогематология. 2018;11(3):241–51. doi: 10.21320/2500-2139-2018-11-3-241-251. [Gudozhnikova Ya.V., Mamaev N.N., Barkhatov I.M., et al. Results of Molecular Monitoring in Posttransplant Period by Means of Series Investigation of WT1 Gene Expression in Patients with Acute Myeloid Leukemia. Clinical oncohematology. 2018;11(3):241–51. doi: 10.21320/2500-2139-2018-11-3-241-251. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2018-11-3-241-251
  59. Patel S, Zhang Y, Cassinat B, et al. Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ⁻/⁻ mice. Leukemia. 2012;26(11):2432–5. doi: 10.1038/leu.2012.154. DOI: https://doi.org/10.1038/leu.2012.154
  60. Ferrari MTM, Elias FM, Gomes NLRA, et al. WT1: A single gene associated with multiple and severe phenotypes. Endocr Metab Sci. 2023;13:100143. doi: 10.1016/j.endmts.2023.100143. DOI: https://doi.org/10.1016/j.endmts.2023.100143
  61. Paubelle E, Plesa A, Hayette S, et al. Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1. Oncol Ther. 2019;7(2):121–30. doi: 10.1007/s40487-019-0095-9. DOI: https://doi.org/10.1007/s40487-019-0095-9
  62. Nguyen CH, Grandits AM, Vassiliou GS, et al. Evi1 Counteracts Anti-Leukemic and Stem Cell Inhibitory Effects of All-Trans Retinoic Acid on Flt3-ITD/Npm1c-Driven Acute Myeloid Leukemia Cells. Biomedicines. 2020;8(10):385. doi: 10.3390/biomedicines8100385. DOI: https://doi.org/10.3390/biomedicines8100385
  63. Geoffroy MC, Esnault C, de Thé H. Retinoids in hematology: a timely revival? Blood. 2021;137(18):2429–37. doi: 10.1182/blood.2020010100. DOI: https://doi.org/10.1182/blood.2020010100
  64. Lübbert ML, Bertz H, Rüter B, et al. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44(9):585–8. doi: 10.1038/bmt.2009.64. DOI: https://doi.org/10.1038/bmt.2009.64
  65. Dӧhner H, Wei AH, Roboz GJ, et al. Prognostic Impact on NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674–85. doi: 10.1182/blood.2022016293. DOI: https://doi.org/10.1182/blood.2022016293

Keywords:

molecular diagnostic panel, acute myeloid leukemia

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Nikolai Nikolaevich Mamaev, Prof., MD, PhD, RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022, e-mail: nikmamaev524@gmail.com

Downloads

Published

01.07.2026

Issue

Vol. 19 No. 3 (2026)
ORIGINAL ARTICLES

How to Cite

Mamaev N.N., Krylova Y.V., Kanunnikov M.M., et al. Developing and Testing of an Original Molecular Panel for Evaluating the Efficacy of Acute Myeloid Leukemia Treatment and Early Diagnosis of Relapses by Quantitative Real-Time PCR. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(3):275–291. doi:10.21320/2500-2139-2026-19-3-275-291.

Most read articles by the same author(s)

1 2 3 4 > >>